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Abstract:  
Background & Aims: Little is known about outcomes of liver transplantation for 
patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency 
and outcomes of liver transplantation for patients with NASH in Europe and identify 
prognostic factors. 
 
Methods: We analyzed data from patients transplanted for end-stage liver disease 
between January 2002 and December 2016 using the European Liver Transplant 
Registry database. We compared data between patients with NASH versus other 
etiologies. The principle endpoints were patient and overall allograft survival. 
 
Results: Among 68,950 adults undergoing first liver transplantation, 4.0% were 
transplanted for NASH – an increase from 1.2% in 2002 to 8.4% in 2016. A greater 
proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma 
(HCC) than non-NASH patients (28.9%, P<.001). NASH was not significantly associated 
with survival of patients (HR 1.02, P=.713) or grafts (HR 0.99; P=.815) after accounting 
for available recipient and donor variables. Infection (24.0%) and cardio/cerebrovascular 
complications (5.3%) were the commonest causes of death in NASH patients without 
HCC. Increasing recipient age (61-65 years: HR 2.07, P<.001; >65: HR 1.72, P=.017), 
elevated MELD (>23: HR 1.48, P=.048) and low (<18.5kg.m-2: HR 4.29, P=.048) or high 
(>40kg.m-2: HR 1.96, P=.012) recipient BMI independently predicted death in patients 
transplanted for NASH without HCC. Data must be interpreted in the context of absent 
recognised confounders, such as pre-morbid metabolic risk factors. 
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Conclusions: The number and proportion of liver transplants performed for NASH in 
Europe has increased from 2002 through 2016. HCC was more common in patients 
transplanted with NASH. Survival of patients and grafts in patients with NASH is 
comparable to that of other disease indications. 
 
Key words:  ELTR database; etiology; long-term follow up; prognosis 
 
Lay Summary:  NASH is a growing indication for liver transplantation in Europe, with 
good overall outcomes, although careful assessment for risk factors is required to 
maintain favorable post-transplant outcomes.  
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Introduction 
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased dramatically, 
in parallel with the worldwide increase in obesity and diabetes1,2.  Approximately a quarter 
of the European adult population have NAFLD, representing an increase of 10% since 
20053.  
 
Non-alcoholic steatohepatitis (NASH) and any associated fibrosis, confer a greater risk 
of liver-related morbidity and mortality amongst patients with NAFLD4.  NASH is an 
increasingly common indication for liver transplantation (LT), and is now second only to 
alcohol-related liver disease  (ARLD) in the United States of America (USA)5. Similarly, 
NASH accounts for an increasing proportion of patients undergoing LT in the UK (4% in 
1995; 12% in 2013)6. However, pan-European data to describe the burden of NASH on 
transplantation services are lacking. 
 
Given the frequent co-existence of obesity, diabetes and related co-morbidities, patients 
with NASH requiring LT are considered to be at a higher risk7. In contrast to the USA8–10, 
European reports of post-transplant outcomes of NASH have been limited to single center 
datasets11. in the absence of well-validated contraindications it remains a challenge to 
effectively risk-stratify patients with NASH being considered for LT7. 
 
We have undertaken a comprehensive analysis of liver transplantation using a 
prospectively updated pan-European database (N=68,950) to determine the frequency 
  
14 
 
and outcomes of patients transplanted for NASH.  Building on this assessment, we have 
identified variables that predict a risk of poorer clinical outcome following LT for NASH. 
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Patients and Methods 
Study Population 
We performed a retrospective cohort analysis of all adult patients (> 18 years old) who 
underwent primary LT for chronic liver disease between 1 January 2002 and 31 
December 2016 using the European Liver Transplant Registry (ELTR) database. A study 
request was reviewed and approved by the ELTR data committee. The ELTR 
prospectively collects LT data from 174 centers in 33 countries and ensures data quality 
and validity by annual audit and cross checking with key European Organ Sharing 
Organizations as previously described12–14.  
 
Data were analyzed for patients transplanted for ARLD, hepatitis C virus infection (HCV), 
hepatitis B virus infection (HBV), autoimmune liver disease (AiLD) (including primary 
sclerosing cholangitis, primary biliary cholangitis and autoimmune hepatitis), cryptogenic 
cirrhosis (CC), NASH and “other” including non-B, non-C chronic viral hepatitis, polycystic 
liver disease, Wilson’s disease, hereditary haemochromatosis and alpha-1-antitrypsin 
deficiency. The cohort included patients who had hepatocellular cancer (HCC) on the 
background of these chronic liver diseases (ELTR database code E1: “Cancers – 
Hepatocellular carcinoma, cirrhosis”). The primary liver diagnosis stated in the ELTR 
database was used to assign diagnoses in these analyses; secondary diagnoses were 
disregarded unless the primary diagnosis was HCC or cryptogenic, for which the 
secondary diagnosis was considered as the primary. Furthermore, patients with a primary 
diagnosis of NASH and a secondary diagnosis of ARLD in the ELTR database were 
assigned a diagnosis of ARLD for the study.  
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For the purposes of this study, patients coded as having cryptogenic disease (ELTR 
database codes D10 “Cirrhosis – other cirrhosis specify”, D11 “Cirrhosis – cryptogenic 
unknown cirrhosis” and E1 [as above] without a second diagnosis in the ELTR) were 
designated as “presumed” NASH if their body mass index (BMI) was  ≥30 kg.m-2, or CC 
if their BMI was <30 kg.m-2. As such, the NASH cohort comprised patients with “pure” 
NASH, defined as those coded as NASH in the ELTR database (F91: “Metabolic disease 
– NASH”), and those with “presumed” NASH as described above8–10,15,16.  
 
Recipient factors analysed included age at transplant, sex, height, weight, BMI, blood 
group, primary liver diagnosis, presence of HCC, serum creatinine, serum bilirubin, 
international normalized ratio (INR) and the Model for End-stage Liver Disease (MELD) 
score. Creatinine, bilirubin and INR had high frequencies of missing data (>50%), and 
thus were not used as independent variables in analyses, but contributed to MELD when 
possible. Of note, other metabolic risk factors including smoking, type 2 diabetes, 
hypertension, hyperlipidemia and a prior history of ischaemic heart disease were not 
included in the dataset. Donor factors included age at death/donation, sex, BMI, blood 
group, and type of donor (donation after circulatory death (DCD), donation after brainstem 
death (DBD), living related donor, domino donor).  
 
Outcome domains comprised of patient and graft survival status, re-transplant rates, 
duration of follow up and causes of death, as coded in the ELTR database. Primary 
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causes of death were used for analyses. Secondary, tertiary and un-coded free-text 
causes of death were considered if the primary cause was coded as other or unknown.   
 
Only data from a patient’s first LT were analysed.  
 
Patient and overall allograft survival were the principle endpoints. Overall allograft survival 
was calculated from the date of primary LT to the date of re-transplantation or date of 
death (event) or the date of last follow up during the period when the transplant was still 
functioning (censored). Death-censored graft survival was not reported due to the high 
proportion of deaths from unknown causes (28.7% overall; 42.2% NASH, 28.2% non-
NASH) which may have made this outcome subject to informative censoring.  
 
For the purpose of survival outcomes analyses and cause of death analyses, patients 
were subdivided into cohorts defined by the presence or absence of concomitant HCC.  
 
The primary comparison of interest was between patients transplanted for NASH and 
those transplanted for other indications (non-NASH). 
 
Statistical Analysis 
Statistical analyses were performed using IBM SPSS Statistics for Windows version 24 
(IBM Corp., Armonk, N.Y., USA), with P-values of <0.05 deemed significant throughout. 
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Parametric continuous variables were summarized with means and standard deviations, 
and groups compared by independent Student t-test, whereas non-parametric continuous 
variables were summarized by median and inter-quartile range (IQR), and groups 
compared by Mann-Whitney U test. Categorical variables were summarized with 
frequencies and percentages, and groups compared by chi-squared test.  
 
Survival outcomes were compared between groups using Kaplan-Meier curves and log-
rank tests. Hazard ratios were calculated using univariable Cox regression models. 
Multivariable Cox regression models were produced to determine whether NASH was 
independently predictive of patient outcome, after accounting for other confounding 
factors. A backwards stepwise approach was used to select factors for inclusion in the 
final model, whereby variables with a significance of P>0.10 were iteratively excluded 
from the input model. All available and clinically relevant factors were included in the input 
models. Where NASH was excluded due to non-significance, it was added into the final 
model alongside the factors identified as significant by the stepwise procedure. The 
analysis was then repeated for the subgroup of patients transplanted for NASH, to identify 
independent predictors of patient survival in this cohort. 
 
For the purposes of Cox regression analyses continuous variables were converted to 
categorical fractions based on conventional thresholds (e.g. WHO classification of BMI), 
or to yield relatively equal numbers of patients in each bracket (in the absence of a widely 
accepted convention). Hazard ratios (HR) from regression analyses were expressed 
relative to a reference category defined either by the group that was closest to 
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physiological normal, the group estimated to have the lowest associated mortality or the 
largest group (HR=1). Specifically, for the model that was produced to identify 
independent predictors of patient survival in NASH patients, risk was assigned against a 
recipient BMI of 25-30 kg.m-2 (N=233), rather than 18.5-25 kg.m-2 (N=71) due to there 
being significantly fewer patients in that bracket, and the recognised curvilinear 
association between BMI and mortality, whereby the perceived lowest risk has shifted to 
a value between 25 and 30 kg.m-2 in more recent years17. 
 
Cases with missing data were excluded on a per-analysis basis. However, three key 
variables had a significant number of missing values – MELD (31.4%), recipient BMI 
(33.7%), and donor BMI (30.2%). We ensured maximal case inclusion in the multivariable 
analyses by including the cases with the missing values by assigning them to a separate 
“missing” category.  
 
The frequencies of deaths due to specific causes were apportioned relative to the total 
number of deaths in patients transplanted for a specific indication. Cause-specific survival 
analyses were then performed using univariable Cox regression models, with 
comparisons between NASH and non-NASH recipients.  
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Results 
Prevalence of NASH as an indication for liver transplantation over time 
After exclusions, 68,950 patients underwent a primary LT for chronic liver disease in the 
study period (Figure 1). NASH was the primary indication in 2,741 patients (4.0%), and 
ARLD was the most common indication (22,226; 32.2%). The proportion of transplants 
performed for patients with NASH increased significantly over time from 1.2% in 2002 to 
8.4% in 2016 (P<0.001) (Figure 2, Supplementary Table 1).  
 
Characteristics of transplant recipients and donors 
In comparison to patients transplanted for other indications (Table 1), recipients with 
NASH were older (median: 60 vs. 55 years, P<0.001) and had a greater BMI (mean: 32.6 
kg.m-2 vs. 25.8 kg.m-2, P<0.001). HCC was more common in recipients transplanted for 
NASH (39.1% vs. 28.9%, P<0.001). Moreover, the proportion of patients with underlying 
NASH amongst those transplanted with HCC increased from 1.3% in 2002-04, to 8.3% in 
2014-16 (P<0.001) (Supplementary Figure 1). Patients with NASH received organs from 
donors who were marginally older (median: 53 vs. 52 years, P=0.030), more likely to be 
male (62.3% vs. 57.6%, P<0.001) and of a greater BMI (26.9 kg.m-2 vs. 25.5 kg.m-2, 
P<0.001) and received more DCD organs (6.6% vs. 2.6%, P<0.001). However, after 
adjusting for the increase in use of DCD organs over time, the rates of DCD use were 
similar in transplants for NASH and non-NASH indications (OR 1.53 (0.21-11.11), 
P=0.677; Supplementary Table 2). Subgroup analyses divided by patients with and 
without HCC identified similar recipient and donor differences between NASH and non-
NASH groups (Supplementary Table 3). 
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Patient survival outcomes after liver transplantation  
There was no significant difference in post-LT patient survival between NASH and non-
NASH recipients (Figure 4), either for recipients without (HR 1.10, 95% CI 0.99-1.22, 
Table 2) or with HCC (HR 1.09, 95% CI 0.97-1.23, Supplementary Table 4). Amongst 
those without HCC, recipients with NASH (N=1,667) had equivalent post-LT survival to 
patients with ARLD (N=17,505, HR 0.95, 95% CI 0.85-1.06) and better survival than those 
with HCV (N=9,007, HR 1.27 (1.14-1.42), P<0.001) (Table 2, Figure 3 panel A). For those 
with HCC, survival in recipients with NASH (N=1,073) was marginally worse than ARLD 
(N=4,715, HR 0.87 (0.76-0.99), P=0.034), but was similar to HCV (N=7,114, HR 1.07, 
95% CI0.94-1.21) and CC (N=3,229, HR 0.93, 95% CI 0.81-1.06) (Supplementary Table 
4, Figure 3 panel B).  
 
On multivariable Cox regression, several recipient and donor characteristics were found 
to be significantly associated with post-LT survival (Table 2, Supplementary Table 4). 
Upon adjusting for these factors, NASH was not found to be a significant independent 
predictor of patient survival, either in patients without (HR 0.97, 95% CI 0.86-1.09) or with 
(HR 1.10, 95% CI 0.97-1.24) HCC. Combining the HCC groups to analyze the cohort as 
a whole returned similar results (HR 1.02, 95% CI 0.93-1.11) (Supplementary Figure 2 
panel A, Supplementary Table 5). 
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Graft survival outcomes after liver transplantation  
On univariable analysis, post-LT graft survival (overall allograft survival) for recipients with 
NASH was comparable to those with non-NASH indications amongst patients without (HR 
1.06, 95% CI 0.96-1.17) and with HCC (HR 1.02, 95% CI 0.91-1.15) (Figure 5, 
Supplementary Table 6). Analyzing the cohort as a whole returned consistent results (HR 
1.06, 95% CI 0.98-1.14) (Supplementary Figure 2, Supplementary Table 5). 
 
Upon adjusting for significant determinants in multivariable Cox regression analyses 
(Supplementary Table 5, Supplementary Table 6), NASH was not found to be a significant 
independent predictor of graft survival, either in patients without (HR 0.98, 95% CI 0.88-
1.09), with (HR 1.02, 95% CI 0.90-1.15), or independent of HCC (HR 0.99, 95% CI 0.91-
1.08).  
 
Causes of death after liver transplantation 
Of patients who died after LT for NASH (N=631) and non-NASH (N=16,989) indications, 
a significant proportion died from unknown causes (NASH: N=266, 42.2%; non-NASH: 
N=4,799, 28.2%; overall = 28.7%).  
 
In recipients without HCC (Supplementary Table 7), infection (N=86, 24.0%), and 
cardio/cerebrovascular complications (N=19, 5.3%) comprised the top two known causes 
of death in patients transplanted for NASH. Infection (N=2,512, 21.6%; HR 1.15 (0.92-
1.42), P=0.216) and cardio/cerebrovascular complications (N=937, 8.1%; HR 0.70 (0.44-
1.10), P=0.123) were also major causes of death in recipients transplanted for non-NASH 
  
23 
 
indications, occurring at similar rates to those observed in NASH. There was a notable 
excess of death from extrahepatic (non-HCC) solid organ malignancy in those 
transplanted for ARLD (N=603, 12.9% vs. N=9, 2.5%), and recurrent disease in those 
transplanted for HCV (N=651, 21.5% vs. N=2, 0.6%), compared to NASH recipients. 
These are reflected in the considerably lower risk of death from extrahepatic malignancy 
(HR 0.41 (0.21-0.79), P=0.008) and recurrent primary liver disease (HR 0.08 (0.02-0.33), 
P<0.001) in NASH than in pooled non-NASH recipients.  
 
Amongst patients with concomitant HCC (Supplementary Table 8), recurrent HCC (N=53, 
19.5%), infection (N=28, 10.3%) and extrahepatic solid organ (non-HCC) malignancy 
(N=18, 6.6%) were the top three causes of death in patients transplanted for NASH. All 
three were also prominent causes of death in those transplanted for other indications, 
although there was again a notable excess risk of death from recurrence of primary (non-
malignant) liver pathology in those transplanted for HCV (N=468, 20.8%) and ARLD 
(N=85, 6.9%) compared to NASH recipients (N=6, 2.2%; P<0.001).  
 
Factors that influence overall survival in patients who are transplanted for 
NASH  
For patients transplanted for NASH in the absence of HCC, a number of recipient (age, 
sex, blood group, BMI, MELD) and donor (blood group) characteristics were found to be 
associated with post-LT survival (Table 3). Subsequent multivariable Cox regression 
modeling revealed that older recipient age (61-65 years: HR 2.07 (1.39-3.08); >65 years: 
HR 1.72 (1.10-2.71); relative to ≤45 years), and MELD score >23 (HR 1.48 (1.04-2.30); 
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relative to ≤11) carried an increased risk of post-LT mortality. In addition, eccentric 
recipient BMI was also associated with poorer post-LT survival; an effect that was more 
pronounced at the extremes (≤18.5 kg.m-2: HR 4.29 (1.01-18.21); 18.5-25 kg.m-2: HR 2.24 
(1.27-3.96); >40 kg.m-2: HR 1.96 (1.16-3.32); relative to 25-30 kg.m-2). Male recipient 
gender (HR 0.79 (0.63-0.98); P=0.031), and blood group B donor organs (HR 0.37 (0.22-
0.63); relative to blood group A) offered a comparative survival advantage.  
 
For patients with NASH and concomitant HCC, none of the available variables were found 
to be significantly associated with survival on either univariable or multivariable analyses 
(Supplementary Table 9).  
 
  
25 
 
Discussion  
This study finds the proportion of transplants for patients with NASH has risen to now 
account for 8.4% of annual transplants in Europe, and reflects rates published from 
national datasets18,19. The trends are in keeping with those seen in the US where NASH 
accounts for more than 18% of transplants8,10,20,21. The magnitude of the impact of NASH 
on transplant services in the US may forecast the future burden in Europe in heed of the 
projected rise of obesity across the continent1,2,22. However, wide intra-continental 
variations in risk factor profiles may limit the local applicability of pan-European data23,24. 
Further to the effect of risk-factors, a greater awareness of NASH, and greater confidence 
amongst transplant physicians to make a diagnosis based on phenotypic associations 
may also contribute to the greater proportion of transplants25. However, the effects of 
ascertainment bias in our study are unlikely to be significant in the absence of a 
commensurate decrease in transplants performed for CC.   
 
There remains controversy in the way large databases establish diagnoses of NASH and 
CC25. In keeping with other large database studies, and to facilitate meaningful 
comparisons between datasets, we have chosen CC patients with a BMI>30kg.m-2 as our 
presumed NASH cohort8–10,15,16. We acknowledge that ascites and edema contribute to 
the BMI and are not corrected for in the ELTR, though this is also a limitation of using 
other large registry databases8. 57.3% of our NASH study cohort were “presumed NASH” 
which is comparable to data from the US; between 45.2%8 and 67.5%9 of the NASH 
cohorts using the UNOS database were “presumed NASH”. However, the differences in 
the characteristics and outcomes between pure and presumed NASH (Supplementary 
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Table 10, Supplementary Figure 3, 4 and 5) highlight that NASH patients are still a 
heterogeneous population and systematically identifying high and low risk subsets based 
on recipient and donor characteristics as highlighted in Table 3, is of critical importance.  
 
A greater proportion of recipients with NASH were transplanted for HCC than non-NASH 
recipients (Table 1). Our findings were in keeping with a recent analysis of the US 
Scientific Registry of Transplant Recipients database26, in which the authors describe an 
7.7-fold increase in the prevalence of NASH in patients transplanted for HCC between 
2002 and 2016. A number of studies have suggested that patients with NASH are at 
greater risk of developing HCC16,21,27, owing partly to the risks associated with obesity 
and insulin resistance28–30. NASH-related HCC is major worldwide concern and left 
unchecked may offset the anticipated declines in primary liver cancer through the control 
of HBV and HCV31.  
 
Amongst the NASH cases, there was a difference in the rates of HCC between the pure 
NASH (28.5%) and presumed NASH (47.1%) cohorts (Supplementary Table 10), due to 
incorporating the orphan E1 ELTR code (Cancers – Hepatocellular carcinoma, cirrhosis; 
no secondary diagnosis) in to the cryptogenic cohort8. The rate of HCC in CC (at the 
exclusion of obese patients) was 46.1% (Supplementary Table 11). 
 
As with other registry studies, readers of our data should be mindful of the potential 
influence of missing data points, despite the vast number of cases included in the study. 
As described in our Methods, a significant proportion of cases in our dataset had missing 
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data for one of MELD, recipient BMI or donor BMI. There were statistically significant 
differences in patient characteristics between cases with and without missing data points 
(Supplementary Table 12). We utilized a “missing-indicator” method to maximally utilize 
the available cases and minimize any loss of statistical power in our multivariable 
analyses. We compared patient survival in those with available data against those with 
missing data. The cases with a missing recipient BMI did not confer a bias to overall 
patient survival (univariable Cox regression; HR 1.01, 95% CI 0.98-1.04, P=0.485) 
compared to cases with available values. Cases with missing MELD (HR 0.93, 95% CI 
0.90-0.96, P<0.001) and donor BMI (HR 0.90, 95% CI 0.87-0.93, P<0.001) did carry a 
weighted risk, although the effect was small. Moreover, we compared multivariable 
models using the missing-indicator method and an “available case analysis” method 
whereby only cases without missing observations are included, and found no significant 
differences to key outcomes (Supplementary Table 13 & 14).  The influence of the 
incomplete data is a recurrent limitation of registry database studies and although 
different statistical methods to account for the effect of missing data are widely used, they 
each carry an inherent bias. Best practice on the statistical methods should be 
incorporated across registries and ideally stated in the standard operating procedures of 
registries.  
 
There were no significant differences in post-LT deaths due to infection and 
cardio/cerebrovascular events between NASH and non-NASH recipients without HCC. 
Conclusions drawn from these data should be tempered in knowledge of the 28.7% of 
cases in which the causes of death were unknown.  However, the loss of data quality with 
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duration of follow up is pervasive to large databases; an analysis of the United Network 
of Organ Sharing (UNOS) database noted that 24% of deaths that occurred 5 years or 
later after transplantation were from unknown causes32. The size of the database cohorts 
may allow for a higher tolerability towards missing data points, but it remains a limitation. 
By comparison, a recent meta-analysis of six single- and two-center studies 
demonstrated an excess of deaths from sepsis (OR 1.71) and cardiovascular causes (OR 
1.65) in the NASH cohort20. 
 
NASH was not found to be an independent predictor of patient or graft survival. These 
results add to a growing body of evidence that suggest current practice in patient selection 
and peri-operative care results in acceptable outcomes for such patients, and reflect good 
utility of donor organs6,10,20. Nevertheless, our findings demand scrutiny of assessing 
transplant risk based on recipient age and BMI. The risk attributed to older recipients is 
particularly pertinent as a growing proportion of transplants are being performed on 
elderly recipients in both the US and Europe33.  Moreover, the risk carried by recipients 
with lower BMI may reflect the independent effects of a catabolic and sarcopenic 
phenotype34. However, the associations at both extremes of BMI are based on relatively 
few patients (N=77 for BMI ≤25 kg.m-2; N=92 for BMI >40 kg.m-2, cp. N=233 for BMI 25-
30 kg.m-2). Critical variables including pre-LT comorbidities, and in particular components 
of metabolic syndrome, may have influenced prognostic determinants in our analysis and 
significantly added to the power of our model11,35. None of our measured variables were 
found to be associated with post-LT mortality in recipients with HCC, which suggests that 
HCC-specific factors that reflect the burden of disease are likely to have a critical influence 
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on post-transplant outcomes36. Tumor specific factors have only been collected by the 
ELTR since 2007, and a dedicated study exploring the influence of these factors on post-
transplant outcomes has recently been published37.  
 
Large databases such as ELTR and UNOS were designed to facilitate research but have 
to compromise between the practicalities of ensuring data collection and the desire to 
capture relevant data fields. Technological developments to optimize data collection and 
periodic review of collected fields in response to evolving knowledge comprise potential 
solutions. Moreover, harmonization of data fields across different registries would allow 
meaningful comparisons between datasets.  
 
In summary, we report a year-on-year increase of LTs done for NASH in the ELTR region 
since 2002. The proportion of transplants done for NASH with concomitant HCC is rising, 
and reflects the widely acknowledged association of NASH with HCC. NASH was not an 
independent predictor of post-LT patient and graft survival. Nevertheless, careful 
assessment and selection of patients will be critical to maintain acceptable survival in 
those transplanted for NASH, with specific scrutiny of female patients, recipients over the 
age of 60, those with advanced liver disease (MELD>23) and particularly patients with 
extreme high or low BMI.  
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Tables 
 NASH 
N=2,741 
Non-
NASH 
N=66,209 
RECIPIENT CHARACTERISTICS 
Age; years; median (IQR)** 60 (54-64) 55 (48-61) 
Sex: male; % 71.1 72.1 
Blood group; %   
A 43.6 43.6 
AB 5.8 5.6 
B 13.0 12.7 
O 37.6 38.1 
BMI; kg.m-2; mean (SD)** 32.6 (4.6) 25.8 (4.4) 
MELD; median (IQR) 16 (12-21) 16 (12-22) 
HCC; % ** 39.1 28.9 
DONOR CHARACTERISTICS 
Age; median (IQR)* 53 (39-61) 52 (37-64) 
Sex: male; %** 62.3 57.6 
Blood group; %   
A 41.8 42.7 
AB 4.5 4.2 
B 11.2 11.7 
O 42.5 41.4 
BMI; kg.m-2; mean (SD)** 26.9 (4.8) 25.5 (4.3) 
Type of donor; % **   
DBD 84.6 90.4 
DCD 6.6 2.6 
Domino 0.8 1.0 
Living 8.0 6.1 
 
Table 1 
Comparison of donor and recipient factors in patients transplanted for NASH and 
non-NASH indications. *P<0.05; **P<0.001 
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 Univariable Multivariable 
 HR (95% CI) 
RECIPIENT CHARACTERISTICS 
NASH (vs non-
NASH) 
1.10 (0.99-1.22) 0.97 (0.86-1.09) 
   
Cirrhosis aetiology Overall** 
n/a 
NASH 1.00 
ARLD 0.95 (0.85-1.06) 
HCV 1.27 (1.14-1.42)** 
AiLD 0.62 (0.56-0.70)** 
HBV 0.68 (0.60-0.77)** 
CC 1.01 (0.90-1.14) 
Other 0.70 (0.62-0.80)** 
Age (years) Overall** Overall** 
</=45 1.00 1.00 
46-55 1.24 (1.18-1.31)** 1.24 (1.18-1.31)** 
56-60 1.46 (1.38-1.55)** 1.49 (1.41-1.59)** 
61-65 1.74 (1.64-1.85)** 1.78 (1.67-1.89)** 
>65 1.94 (1.80-2.09)** 2.04 (1.89-2.20)** 
Sex: male 1.12 (1.07-1.16)** 1.11 (1.06-1.15)** 
MELD Overall** Overall** 
≤11 1.00 1.00 
>11, ≤14 0.97 (0.89-1.07) 0.98 (0.89-1.07) 
>14, ≤18 0.99 (0.91-1.07) 1.02 (0.94-1.11) 
>18, ≤23 1.00 (0.92-1.09) 1.05 (0.96-1.15) 
>23 1.48 (1.37-1.60) 1.52 (1.40-1.64)** 
Missing value 1.15 (1.07-1.24) 1.22 (1.12-1.33)** 
Blood group Overall Overall* 
A 1.00 1.00 
AB 0.98 (0.90-1.06) 1.18 (1.01-1.38)* 
B 0.99 (0.94-1.05) 1.12 (0.95-1.31) 
O 1.00 (0.96-1.04) 0.94 (0.84-1.07) 
BMI (kg.m-2) Overall** Overall** 
≤18.5 1.20 (1.06-1.36)* 1.34 (1.18-1.52)** 
>18.5, ≤25.0 1.00 1.00 
>25.0, ≤30.0 1.00 (0.95-1.06) 0.95 (0.90-1.01) 
>30.0, ≤35.0 1.09 (1.02-1.17)* 1.04 (0.97-1.12) 
>35.0, ≤40.0 1.09 (0.96-1.23) 1.06 (0.93-1.21) 
>40.0 1.35 (1.10-1.67)* 1.35 (1.09-1.67)* 
Missing value 1.02 (0.97-1.07) 1.04 (0.98-1.11) 
DONOR CHARACTERISTICS 
Age (years) Overall** Overall** 
</=34 1.00 1.00 
35-47 1.19 (1.13-1.27)** 1.16 (1.09-1.23)** 
48-57 1.30 (1.22-1.37)** 1.25 (1.18-1.33)** 
  
38 
 
58-67 1.45 (1.37-1.54)** 1.38 (1.29-1.47)** 
>68 1.63 (1.54-1.73)** 1.52 (1.43-1.62)** 
Sex: male 0.99 (0.95-1.03) not in final model 
Blood group Overall Overall* 
A 1.00 1.00 
AB 0.91 (0.83-1.00) 0.82 (0.68-0.97)* 
B 0.96 (0.91-1.02) 0.90 (0.76-1.06) 
O 1.02 (0.98-1.06) 1.07 (0.95-1.21) 
BMI (kg.m-2) Overall** Overall** 
≤18.5 0.92 (0.80-1.06) 0.91 (0.79-1.06) 
>18.5, ≤25.0 1.00 1.00 
>25.0, ≤30.0 1.10 (1.05-1.15)** 1.02 (0.97-1.07) 
>30.0, ≤35.0 1.09 (1.01-1.18)* 1.02 (0.94-1.11) 
>35.0, ≤40.0 1.10 (0.95-1.28) 1.02 (0.88-1.19) 
>40.0 0.89 (0.69-1.15) 0.85 (0.66-1.10) 
Missing value 0.92 (0.88-0.96) 0.85 (0.80-0.90)** 
Type of donor Overall** Overall** 
DBD 1.00 1.00 
DCD 0.68 (0.59-0.79)** 0.73 (0.62-0.85)** 
Domino 1.20 (1.00-1.23) 1.20 (0.99-1.45) 
Living 1.14 (1.05-1.23)** 1.43 (1.31-1.56)** 
OTHER VARIABLES 
Re-transplant 1.76 (1.67-1.86)** 1.80 (1.71-1.91)** 
Era of transplant Overall** Overall** 
2002-2004 1.00 1.00 
2005-2007 1.05 (0.99-1.10) 1.03 (0.98-1.09) 
2008-2010 1.13 (1.07-1.19)** 1.07 (1.00-1.13)* 
2011-2013 1.00 (0.94-1.06) 0.93 (0.87-0.99)* 
2014-2016 0.87 (0.80-0.93)** 0.81 (0.75-0.89)** 
 
Table 2 
Recipient and donor factors that influence patient survival in transplant recipients 
without HCC. The final multivariable models based on 47,040 patients. *P<0.05; 
**P<0.001 
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 Univariable Multivariable 
 HR (95% CI) 
RECIPIENT CHARACTERISTICS 
Age (years) Overall* Overall** 
≤45 1.00 1.00 
46-55 1.17 (0.79-1.76) 1.31 (0.87-1.98) 
56-60 1.08 (0.71-1.62) 1.23 (0.81-1.87) 
61-65 1.71 (1.16-2.52)* 2.07 (1.39-3.08)** 
>65 1.50 (0.96-2.33) 1.72 (1.10-2.71)* 
Sex: male 0.74 (0.60-0.92)* 0.79 (0.63-0.98)* 
MELD Overall** Overall** 
≤11 1.00 1.00 
>11, ≤14 0.96 (0.63-1.48) 1.03 (0.66-1.62) 
>14, ≤18 0.65 (0.43-0.98)* 0.66 (0.44-1.06) 
>18, ≤23 0.68 (0.44-1.05) 0.71 (0.47-1.15) 
>23 1.41 (0.97-2.05) 1.48 (1.04-2.30)* 
Missing value 0.83 (0.52-1.32) 0.93 (0.57-1.51) 
Blood group Overall* 
not in final model 
A 1.00 
AB 0.84 (0.53-1.33) 
B 0.56 (0.37-0.85)* 
O 1.02 (0.82-1.27) 
BMI (kg.m-2) Overall* Overall* 
≤18.5 2.58 (0.62-10.72) 4.29 (1.01-18.21)* 
>18.5, ≤25.0 1.98 (1.13-3.47)* 2.24 (1.27-3.96)* 
>25.0, ≤30.0 1.00 1.00 
>30.0, ≤35.0 1.22 (0.85-1.74) 1.38 (0.95-2.01) 
>35.0, ≤40.0 1.38 (0.92-2.08) 1.43 (0.93-2.18) 
>40.0 1.92 (1.15-3.18)* 1.96 (1.16-3.32)* 
Missing value 0.89 (0.41-1.92) 1.13 (0.49-2.63) 
DONOR CHARACTERISTICS 
Age (years) Overall 
not in final model 
≤45 1.00 
46-55 1.15 (0.82-1.62) 
56-60 1.15 (0.83-1.59) 
61-65 1.20 (0.85-1.69) 
>65 1.28 (0.88-1.84) 
Sex: male 0.97 (0.78-1.20) not in final model 
Blood group Overall* Overall* 
A 1.00 1.00 
AB 0.83 (0.49-1.41) 0.99 (0.58-1.70) 
B 0.39 (0.23-0.65)** 0.37 (0.22-0.63)** 
O 1.05 (0.85-1.31) 1.06 (0.85-1.32) 
BMI (kg.m-2)  
not in final model ≤18.5 1.85 (0.59-5.83) 
>18.5, ≤25.0 1.13 (0.89-1.43) 
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>25.0, ≤30.0 1.00 
>30.0, ≤35.0 0.98 (0.70-1.36) 
>35.0, ≤40.0 0.69 (0.34-1.40) 
>40.0 1.15 (0.54-2.45) 
Missing value 0.73 (0.44-1.20) 
Type of donor Overall 
not in final model 
DBD 1.00 
DCD 0.79 (0.47-1.33) 
Domino 1.16 (0.29-4.64) 
Living 1.45 (1.02-2.05) 
OTHER VARIABLES 
Era of transplant Overall 
n/a 
2002-2004 1.00 
2005-2007 0.90 (0.59-1.37) 
2008-2010 1.18 (0.79-1.76) 
2011-2013 1.09 (0.72-1.63) 
2014-2016 1.13 (0.74-1.71) 
 
Table 3 
Recipient and donor factors that significantly affect post-transplant survival in 
patients transplanted for NASH without HCC. The final multivariable models based 
on 1,628 patients. *P<0.05; **P<0.001 
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Figure Legends 
 
Figure 1 
Flow chart of case selection from the ELTR database. 
 
Figure 2 
Trends of annual primary LTs performed for different indications in the ELTR 
region.  
 
Figure 3 
Survival analysis for patients undergoing primary liver transplantation for 
different indications. Kaplan-Meier curves of patient survival for cases without (A), and 
with (B) HCC (log-rank: P<0.001 for both).  
 
Figure 4 
Survival analysis for patients with and without HCC undergoing primary LT for 
NASH and non-NASH indications. Kaplan Meier analysis demonstrated no significant 
survival differences between patients transplanted for NASH and non-NASH indications 
amongst those without HCC (log-rank: P=0.081) or with HCC (log-rank: P=0.155). 
There is a significant difference between patients transplanted with and without HCC 
overall (log-rank: P<0.001).  
 
Figure 5 
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Overall allograft survival analysis for patients undergoing primary liver 
transplantation for different indications. Kaplan-Meier curves of overall allograft 
survival for cases without (A), and with HCC (B) (log-rank: P<0.001 for both).  
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Highlights:  
 
 An increasing proportion of patients are being transplanted for NASH in Europe. 
 Hepatocellular carcinoma was more common in patients transplanted with NASH.  
 Survival in recipients with NASH is comparable to that of other disease indications. 
 Age, BMI, and advanced liver disease predicted poorer outcomes in NASH 
recipients. 
 
 
 
 
